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Abstract
AIM: An investigation into inflammatory bowel disease and
colorectal cancer in Veszprem Province was conducted from
1977 to 2001.
METHODS: Both hospital and outpatient records were
collected and reviewed comprehensively. The majority of
patients were followed up regularly.
RESULTS: The population of the province was decreased
from 386 000 to 376 000 during the period. Five hundred
sixty new cases of ulcerative colitis (UC), 212 of Crohn’s
disease (CD), and 40 of indeterminate colitis (IC) were
diagnosed. The incidence rates increased from 1.66 to 11.01
cases per 100 000 persons for UC, from 0.41 to 4.68 for CD
and from 0.26 to 0.74 for IC. The prevalence rate at the end
of 2001 was 142.6 for UC and 52.9 cases per 100 000 persons
for CD. The peak onset age in UC patients was between 30
and 40 years, in CD between 20 and 30 years. A family
history of IBD was present in 3.4 % in UC and 9.9 % in CD
patients. Smoking increased the risk for CD (OR=1.94) while
it decreased the risk for UC (OR=0.25). Twelve colorectal
carcinomas were observed in this cohort, the cumulative
colorectal cancer risk after 10 years in UC was 2%, after
20 years 8.8%, after 30 years 13.3%.
CONCLUSION: The incidence and prevalence rates of IBD
have increased steadily in Veszprem Province, now equivalent
to that in Western European countries. Rapid increase in
incidence rates supports a probable role for environmental
factors. The rate of colorectal cancers in IBD is similar to
that observed in Western countries.
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INTRODUCTION
The pathogenesis of ulcerative colitis (UC) and Crohn’s disease
(CD) has only been partly understood. Inflammatory bowel
disease (IBD) is a multifactorial polygenic disease with
probable genetic heterogeneity. Based on this hypothesis,
the disease may develop in a genetically predisposed host
as a consequence of disregulated immune response to
environmental factors, in particular enteric antigens, resulting
in continuous immune-mediated inflammation[1,2]. However,
the disease phenotype may be affected by various other
factors.
     IBD represents an important public health problem, as it
tends to afflict young people and has a protracted and relapsing
clinical course, affecting education, working abilities, social
life and quality of life.
      Several studies have been done on the epidemiology of
IBD [3,4].  The geographical incidence of IBD varies
considerably, the highest incidence rates were reported in
Northern and Western Europe as well as North America,
whereas they were lower in Africa, South America and Asia,
including China[5]. It is more common in developed, more
industrialized countries, urban residency seems to be a risk
factor. The incidence rate of UC varies greatly between 0.5-
24.5/100 000 inhabitants, that of Crohn’s disease between
0.1-11/100 000 inhabitants worldwide.
      Previous studies in Europe suggested that the incidence
was decreased from North to South[6,7], but in the early nineties
the European IBD Study Group found comparable rates in
Southern and Northern Europe[8]. This tendency may be
explained by the relative stable incidence in previous high
incidence areas, whereas in previous low incidence areas the
incidence rose continuously. A further difference is that the
previously reported predominance of UC is diminishing, as
CD is becoming more prevalent. The reported average
incidence of UC in Europe was 10.4, that of CD was 5.6.
      Few data have been available about the frequency of IBD
in the Eastern European countries. In the early eighties,
Vucelic et al.[9,10] conducted a prospective survey on the
incidence of IBD in Zagreb, Croatia. They reported an
incidence rate of 1.5/100 000 inhabitants in UC and 0.7 in
CD. Similarly low incidence of UC (1.7) and CD (1.4) was
reported in another prospective study in Estonia[11]. Nagy
et al.[12] reported epidemiological data in IBD from the early
60’s to the late 80’s among Hungarians. The reported
incidence rate was 3.6 in UC and 1.0 in CD. These data were
based mainly on hospital reports. No population based survey
has been reported.
      The elevated colorectal cancer (CRC) risk in patients with
long standing IBD has been widely accepted since Crohn’s
original report. Recent observations suggested that the
prevalence of CRC was also higher in CD[13]. The magnitude
of the risk complicating IBD varied greatly in different
geographic areas and in different studies. From Eastern Europe
we found only one publication about CRC in IBD[14].
      Recently we reported on the prevalence of extraintestinal
manifestations in a large IBD cohort in a long-term follow-up
study[15]. The aim of the present study was to determine the
incidence and prevalence of IBD and the main epidemiological
features of the disease in a province of Hungary in a population
based survey.
MATERIALS AND METHODS
Demographical data
Veszprem Province is located in the Western part of Hungary.
The province consists of both industrial and agricultural
regions.
      The number of permanent population was relatively stable,
with a slight decrease from 386 462 to 376 211 from 1980 to
1998 (Table 1). The rate of Gypsies is below the Hungarian
average (2.5%), few Jewish people live in the province. The
ratio of urban/rural residence was also relative stable (the data
in 1991 were used for comparison, Table 2).
       There are 7 general hospitals in the province, each is staffed
by at least one gastroenterologist or internist with special
interest in gastroenterology. The majority of the patients (74%
of UC patients and 94% of CD patients) were followed-up in
the Csolnoky F. Province Hospital in Veszprem. The main
data sources were the hospital records, outpatient clinical
reports, endoscopical, radiological and pathological reports
collected from the Internal Medicine Department, Surgery
Department, Outpatient Units and family doctors. Both
inpatients and outpatients permanently residing in the
investigated area were included in the study. Most of the
patients were followed up regularly. Diagnoses (based on
hospitalization records, outpatient visits, endoscopic,
radiological and histological evidence) generated in each
hospital and outpatient unit were reviewed thoroughly, using
the Lennard-Jones criteria[16].
     Cases having another readily identifiable cause of colitis,
such as infectious colitis (including pseudomembranous) were
excluded. Anticoncipient or NSAID associated colitis and
ischemic colitis cases were also excluded. UC cases with
involvement outside the colon, with the exception of
“backwash ileitis”, were excluded. In some cases the final
diagnosis was made years after the beginning of symptoms.
      The term indeterminate colitis (IC) was first described by
Price in 1978[17] for cases operated on because of non-
differentiable fulminating colitis. Today it has been used for
IBD colitis cases, when the data were insufficient to differentiate
between UC and CD[8].
     Before the early eighties the diagnosis was based mainly
on rectoscopy, histology, barium enema and upper GI series.
Later colonoscopy, double-contrast barium enema and selective
enterography were the basic diagnostic methods, CT and in
some cases leukocyte scintigraphy were also more frequently
performed to help make a more accurate diagnosis (e.g.
location, activity and complications).
      The location in UC was determined by colonoscopy and/or
double-contrast colonography based on the macroscopic
picture. Patients were classified according to the greatest known
extent. In mild to moderately severe active UC cases the
location was determined during the active phase, in more severe
disease shortly after the active period.
     The study was retrospective. Data of IBD patients were
summarized yearly, in some cases the diagnosis was changed
after re-evaluation. IBD patient data were collected every year
from the 7 general hospitals and gastroenterology outpatient
units. The provincial IBD register data were centralized in
Veszprem, which is the secondary referral center for IBD
patients in the province. Patients diagnosed in the same calendar
year were included in the incidence calculations. All the
residents and IBD patients permanently residing in the province
on the 31st of December 1991 and 2001 were included in the
prevalence calculations (including patients who had moved to
Veszprem Province after diagnosis).
      Regular colonoscopic dysplasia-cancer surveillance program
with multiple biopsies was carried out in patients with extensive
colitis after 8 years, with left-sided colitis after 12 years.
       The source of demographic data was the Hungarian Central
Statistical Office (KSH).
Table 1  Population of Veszprem Province between 1980-1998
Years   Total Women   Men
1980 386.462 194.855 191.607
1990 379.246 192.867 186.462
1998 376.211 192.296 183.915
Male/female ratio in 1990: 0.966.
Table 2  Proportion of patients according to places of residence
(in 1991) (OR: Odds ratio)
Urban (n) Rural (n) Total (n)
Veszprem Province   208.284 173.089 381.373
Ulcerative colitis   339 221 560
              OR: 1.27
      (95% CI: 1.07-1.52)
Crohn’s disease   122   90 212
              OR: 1.13
      (95% CI: 0.85-1.49)
Statistical methods
For statistical comparison of the data, Statistica 6.0 (Statsoft
Inc., USA) was used. Odds ratio (OR) was calculated for potential
factors that influenced the prevalence of IBD, including residence
(urban versus rural) and smoking habits. For comparisons within
group ANOVA analysis with Scheffe post hoc test was used.
Yates-corrected Chi-square analysis was performed to compare
differences in incidence according to the location of UC or CD
during the observed period. Results were expressed as mean±SD
if otherwise not stated (NS=not statistically significant).
RESULTS
Incidence
During the observation period 560 new patients with UC (M/F:
288/272, ratio: 1.058) and 212 new patients with CD (M/F:
108/104, ratio: 1.038) were diagnosed in Veszprem Province.
      The mean incidence rate for UC was 5.89 (95%CI: 2.15-
9.63) cases per 100 000 persons per year. The sex-standardized
incidence appeared slightly higher in men (6.19, 95%CI:
2.30-10.08) than in women (5.64, 95%CI: 2.39-8.89), however,
the difference was not statistically significant. For the
calculation of the sex standardized incidence rates, gender
specific population data of Veszprem Province were used
(Hungarian Central Statistical Office, KSH). In CD the average
25-year incidence was 2.23 (95%CI: 0.5-3.96), in men: 2.31
(95%CI: 0.64-3.98 and in women: 2.17 (95%CI: 0.34-4).
Indeterminate colitis was diagnosed in forty cases (M/F: 22/18),
the mean incidence rate was 0.42 cases per 100 000 persons
per year.
      The incidence of IBD in 5-year intervals is shown in Figure
1. A sharp increase in incidence of UC was observed from
1.66 during 1977-1981 to 11.01 during 1997-2001 (in men from
1.77 to 11.96 and in women from 1.54 to 10.09). For CD, a
similar tendency was observed. The incidence rose from 0.41
to 4.68, in men from 0.21 to 5.76, in women from 0.41 to 3.64.
An almost continuous rise in incidence was observed for both
UC and CD. The incidence of IC also rose during the observed
period (from 0 to 0.74).
     In contrast to UC, for which the highest incidence rate
recorded was in 2001 in both sexes (in men 16.85, in women
11.96), for CD the peak incidence recorded in men was 9.24
in 1998, whereas in women it was 5.72 in 2001.
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      The ratio of UC/CD incidence rates decreased from 4.05 to 2.
35 during the observed periods.
Figure 1  Average and sex-specific incidence of UC, CD and IC
in Veszprem Province between 1977-2001.
Age standardized incidence rates
The mean age at diagnosis was 31.7±12.8 years for CD,
38.9±15.5 years for UC and 36.8±13.9 years for IC. For the
calculation of age standardized incidence rates, age specific
population data of Veszprem Province were used (Hungarian
Central Statistical Office, KSH). We observed only one peak
incidence. For UC the highest incidence rate was in 31-40-
year olds, but the 21-30-year olds incidence rate was in the
same range (10.96 vs 9.26). For CD the peak incidence was in
the 21-30-year olds (Figures 2A and B). The youngest UC
patient was diagnosed at the age of 9 years, while the oldest
patient just passed 80 years at the time of diagnosis. The youngest
CD-diagnosed-patient was 12, the oldest 80 years old.
Prevalences
All the patients permanently living in Veszprem Province were
included in the prevalence calculation (even patients diagnosed
before 1977, 33 UC cases and 3 CD cases were not included
as incidence cases).
      On the 31st of December 1991, the prevalence of UC was
59.2 cases per 100 000 persons, that of CD was 17.1 cases per
100 000 persons. On this day the prevalence of IC was 2.9/
100 000. The prevalences were significantly increased by the
31st of December 2001. For UC the prevalence was 142.6, while
for CD 52.9 cases per 100 000 persons.
      The urban/rural ratio was 1.205 in general population in 1991,
which was relatively stable during the observed period. Urban
residency seemed to increase the risk of UC (OR: 1.27), but it did
not affect significantly the risk for CD (Table 2).
Figure 2  Age and sex-specific incidence of UC and CD in
Veszprem Province between 1977-2001.
Figure 3  Location of UC or CD (n=number of patients).
Location and disease behavior
According to our information 112 of the UC patients had
proctitis, 162 proctosigmoiditis, 117 left sided colitis, 84
subtotal and 85 pancolitis (Figure 3A). The age at diagnosis
did not affect the location of the disease.
     Location of UC did change in the past 25 years, proctitis
became more prevalent in the last decade compared to the first
10 years (8.6% vs 24.0%, P=0.002), while pancolitis cases
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were relatively less frequent (39.8% vs 27.8%, P=0.034). The
percentage of left sided colitis did not change (51.6% vs 48.2%).
      The Vienna classification[18] defines CD patients according
to the age at onset, location and disease behavior. In CD ileal
disease (L1) was found in 32.1%, colonic (L2) in 26.9% and
ileocolonic (L3) in 41.0% of the patients (Figure 3B). Location
of CD did also change in the observed period. There was a
tendency of colonic location becoming more frequent in the
last decade compared to the first one, while the percentage of
ileocolonic cases was decreased (L1: 19.2% vs 24.1%, P=NS,
L2: 19.2% vs 36.5%, P=NS, L3: 61.5% vs 39.4%, P=0.05).
The most commonly associated location was perianal (48
cases). All the patients with upper gastrointestinal location (L4)
had lower gastrointestinal involvement, and were classified
according to this location (L1-3). In 5 cases the jejunum, in 2
the duodenum, in 5 the stomach and in 2 the esophagus were
also affected. Only histologically proven cases were included
in the calculation of associated locations. There was no
correlation between the location and age at diagnosis.
     According to the disease behavior 63 of our CD patients
were defined as non-stricturing, non-penetrating (B1), 54 as
stricturing (B2) and 95 as penetrating (B3). Fifty-three patients
of the 95 penetrating cases had parallel strictures.
      In UC group 6.4% of the patients had at least one bowel
operation, a much higher frequency was observed in CD (60%,
Table 5). There was an association between disease location
and the frequency of operations (L1=0.98, L2=0.21, L3=1.93
operations on average, P<0.01 among all the groups, ANOVA-
Scheffe post hoc test).
Familial incidence
Of the UC patients 19 had one or more close relatives with
confirmed UC or CD (Table 3). In CD patients IBD was
apparent in 9.9% of the families. The occurrence of IBD was
more pronounced in families of CD patients with stricturing
disease than in those of CD cases with non-stricturing, non-
penetrating disease (B1: 6.6% (4/60), B2: 24.5% (13/53) and
B3: 11.7% (11/94), P=0.04).
Table 3  Familial occurrence of IBD
Relationship UC (n=560) CD (n=212)
First-degree relative with IBD          17                      15
Second-degree relative with IBD            2                        6
Familial IBD            3.4 %                 9.9%
Smoking
Sixty-seven UC patients (14.3%) were smokers at the time of
diagnosis, while the rate of ex-smokers and nonsmokers was
18.4% and 67.3%, respectively (Table 4). In CD patients 102
were smokers at the time of diagnosis (50.5%, which was higher
than the Hungarian average of 40.5%, 1991 data, KSH).
Among the patients with CD, 13 ex-smokers and 87
nonsmokers were identified. Smoking decreased the risk for
UC by 75%, while it almost doubled the risk for CD (OR: 1.94,
95% CI: 1.46-2.59).
Colorectal carcinoma
Colon tumor was observed in 10 patients with UC (Table 6).
The average duration of IBD at the diagnosis of colorectal
cancer was 18.4 years. The average age at the diagnosis of
CRC was 53.4 (27-65) years, 15 years younger than the age of
patients with non-IBD CRC at diagnosis (68.2 years, 2000 data,
KSH). The male/female ratio was one (5/5). Seven out of the
ten patients had pancolitis. Two colorectal cancers occurred
in CD patients with a short follow-up (3 and 6 years) period.
The location of CD was colonic without ileal involvement. No
family history of IBD was apparent in IBD cases with CRC.
Only one out of the twelve patients with IBD and CRC had a
family history of CRC.
      The cumulative risk for colorectal cancer in patients with
UC for 10 years was 2%, for 20 years 8.8%, and for 30 years
13.3%, respectively.
Table 4  Smoking habits in IBD patients at presentation
    UC n (%)  CD n (%)
Non-smoker    315 (67.3%) 87 (43.1%)
Ex-smoker      86 (18.4%) 13 (6.4%)
Smoker      67 (14.3%) 102 (50.5%)
No data      92 10
Odds ratio for smoking        0.25 (95% 1.94 (95%
    CI: 0.19-0.32) CI: 1.46-2.59)
(Prevalence of smoking in Hungary in 1991: 40.5%).
Table 5  Surgery in IBD
Surgery in UC Surgery in CD
   Resection: 8 Not operated: 86 (40.6 %)
   Proctocolectomy: 28 Operated: 126 (59.4 %)
                  - J Pouch: 25     1 operation: 63 (29.7 %)
    2-3 operations: 50 (23.6 %)
    4-8 operations: 13 (6.1 %)
Table 6  Colorectal carcinoma in IBD
Carcinomas   Age at         Duration      Location        Location
diagnosis        of IBD          of IBD          of tumor
UC (n=10)             35 yrs          18.4 yrs  Pancolitis: 7   Ascending: 2
             (20-56 yrs)     (9-33 yrs)  Left sided       Transverse: 4
 colitis: 3          Descending: 2
            Rectum: 2
CD (n=2)   24 and            3 and  Right             Transverse: 2
   45 yrs             6 yrs  colon: 2
DISCUSSION
The incidence of IBD varied greatly worldwide. Genetic and
environmental factors were assumed to play a significant role
in the etiology of the disease[1,2]. The role of genetic factors
was supported by ethnical and familial differences and also
by twin studies[19-22], while the differences in incidence rates
among various geographical areas suggest a role for certain
environmental factors. There has been an important change
in incidence of IBD in the last few decades. In high incidence
countries in Western Europe the incidence rate remained
relatively stable, while in previous low incidence areas[9,12]
as supported by our data as well, the disease has become
more common.
      The continuous increase in incidence rates of both UC and
CD observed in this study raises further questions. What could
be the cause of this change? In the first years the lower incidence
rates could be explained partly by the use of less up-to-date
diagnostic procedures (e.g. the relative low availability of
selective enterography or colonoscopy). It is possible that better
awareness, either by physicians or by patients, may result in
the diagnosis of mild cases that previously might have gone
unnoticed. There has also been an important change in patients’
behavior in Hungary, as patients tend to seek medical advice
more often and with milder symptoms than they did two
decades ago. We believe that the increase in the incidence of
IBD in the second part of the observed period is real and not
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solely due to an improved diagnosis or more extensive search.
This idea is also supported by the increase in severe cases that
could only be interpreted as real. Our incidence rates in UC (11.01)
and CD (4.68) in the last five-year period (1997-2001) were in
the range as previously observed in high incidence Nordic
countries[7,8,23,24] and they were much higher than the rates
reported in Hungary two decades ago[12].
      Most studies reported the peak onset of both UC and CD at
late puberty - early adulthood period. In some studies a second
peak of onset was observed in 50-70 year-olds[25]. The EC-IBD
study[8] reported one peak onset in CD in both sexes around
the age of 20 (incidence rate in men was around 6.0 and in
women 7.7) followed by a continuous decrease. In UC the peak
incidence was observed in both sexes in 25-30-year olds
(incidence rate was 11.2 in men and 10.7 in women), followed
by a continuous decrease in women, while the incidence
remained relatively stable in men. In the present study we
observed one peak incidence in UC in 30-40 year olds (in men
10.0 and in women 12.1) and also in CD in 20-30 year olds (in
men 5.2 and in women 5.9).
     IBD could affect both sexes almost equally, with a slight
predominance of women in CD, and a male/female ratio
ranging from 1.1 to 2.0 in UC[5,8,23]. In our present study the
male to female ratio was almost similar with a slight male
predominance.
      In UC the proportion of extensive colitis was higher, while
the percentage of proctitis cases was lower than those in the
recent EC-IBD study[8]. Location of UC cases only mildly
changed in the observed period. The percentage of pancolitis
cases was decreased, in contrast, procitis became more
prevalent. However it was still less frequent than observed in
the Western-European epidemiological studies[8].
      In CD ileal disease was found in one third of the patients,
and ileocolonic in 41.0% of the patients. A recent study reported
a higher frequency of ileocolonic disease while the percentage
of ileal disease was lower[8]. In the current study colonic
involvement was observed in almost two-thirds of the patients,
and there seemed to be a shift from ileal to colonic location
during the observed period.
     The rapid increase in incidence rates might support a role
for possible environmental factors[26]. Diet, as a luminar antigen
was thought to be an important factor in the pathogenesis of
IBD[1,27]. In the last two decades there has been a change in the
lifestyle in Hungary, as the standard way of living including
the diet became more “Western”. Other possible environmental
factors, such as perinatal events, infections in childhood or
measles have not been investigated in this study[26,28,29]. Measles
vaccination is universal in Hungary, and the disease is very
rare. The birth rate is one of the lowest ones in Europe. Early
childhood hygiene is developed, supporting the “oversheltered
child” theory[30].
      One of the most important environmental factors considered
in the etiology of IBD was smoking[1,31]. In concordance with
previous data we could identify smoking as a protective factor
in patients with UC (OR: 0.25). In contrast, smoking increased
the risk for CD almost 2-fold.
      The percentage of operations in UC in our study was below
the 10-20% rate reported in most series. The reason for this could
be the more conservative practice in Hungary and also the greater
resistance of patients to surgery. The majority of the operations
were proctocolectomies with ileal pouch anal anastomosis (IPAA).
The proportion of surgically treated patients in CD was similar to
that previously published (60-80%). Almost one third of the CD
patients had multiple operations.
      There is an increased risk of CRC in IBD, but the reported
incidence rates varied greatly. Earlier studies from tertiary
referral centers reported rather high cumulative incidence rates
of CRC (>10% at 20 years, >30% at 30 years). However, it might
reflect referral biases, because of overrepresentation of more
serious diseases in these centers that did not represent the
usual spectrum of IBD[32]. In population-based studies, that
followed a larger number of patients for a long time, in a certain
area, lower CRC rates were reported (5.5% at 20 years, 13.5%
at 30 years). The rate of colorectal cancers in our study was
similar to that reported in previous population-based studies.
      The two most important risk factors were the disease duration
and extent (in CD the colonic involvement)[32,33]. Other factors
involved are early age at onset, pharmacotherapy, disease
activity (relapsing-chronically active, number and severity of
relapses), smoking habits, family history of CRC, the presence
of primary sclerosing cholangitis, backwash ileitis. In our study
the UC patients with CRC were non-smokers while the two
CD patients were smokers during the follow-up, however our
numbers were relatively small to make a reasonable conclusion.
      Prophylactic colectomy, regular mesalamine and folic acid
treatment, and colonoscopic surveillance might reduce the
elevated CRC risk[34,35]. In our study all the patients with IBD
and CRC received 5-ASA. In concordance with previous
results CRC was diagnosed in only one out of 32 patients
with UC and in none of 66 patients with CD taking
azathioprine, such azathioprine did not seem to increase
cancer risk. Colonoscopic surveillance was the most widely
used method to reduce CRC risk, but evidences of its benefits
were controversial[36,37]. We also performed colonoscopic
surveillance, which might have reduced cancer risk.
      There is an additional increased risk of both colorectal and
hepatobiliary malignancies in the subset of patients with
primary sclerosing cholangitis (PSC) and IBD[38]. In our cohort
three colorectal carcinomas developed in the 13 PSC patients,
showing an increased risk in this subgroup. The reason for the
short interval (3 and 6 years) between the diagnosis of CD and
colorectal cancer is not clear. One may hypothesize that the
asymptomatic course of IBD may be responsible for the early
occurrence of colorectal cancers.
     In conclusion, the incidence and prevalence have been
steadily rising in the last 25 years and Now it reaches the levels
reported in Western European countries. We observed no
gender differences. There was a relative high incidence of
colorectal cancers in IBD, similar to Western countries. The
cause of the continuous rapid increase in the incidence of IBD
is unknown, but the incidence supports a possible role for
environmental (e.g. diet, lifestyle) factors.
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